vs

Side-by-side financial comparison of Canaan Inc. (CAN) and OCULAR THERAPEUTIX, INC (OCUL). Click either name above to swap in a different company.

Canaan Inc. is the larger business by last-quarter revenue ($20.8M vs $13.3M, roughly 1.6× OCULAR THERAPEUTIX, INC). Canaan Inc. runs the higher net margin — -18.4% vs -488.0%, a 469.5% gap on every dollar of revenue.

Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.

Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.

CAN vs OCUL — Head-to-Head

Bigger by revenue
CAN
CAN
1.6× larger
CAN
$20.8M
$13.3M
OCUL
Higher net margin
CAN
CAN
469.5% more per $
CAN
-18.4%
-488.0%
OCUL

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
CAN
CAN
OCUL
OCUL
Revenue
$20.8M
$13.3M
Net Profit
$-3.8M
$-64.7M
Gross Margin
99.9%
88.0%
Operating Margin
-15.9%
-526.5%
Net Margin
-18.4%
-488.0%
Revenue YoY
-22.4%
Net Profit YoY
-33.6%
EPS (diluted)
$-0.05
$-0.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CAN
CAN
OCUL
OCUL
Q4 25
$20.8M
$13.3M
Q3 25
$13.8M
$14.5M
Q2 25
$11.4M
$13.5M
Q1 25
$10.7M
Q4 24
$17.1M
Q3 24
$10.2M
$15.4M
Q2 24
$4.8M
$16.4M
Q1 24
$14.8M
Net Profit
CAN
CAN
OCUL
OCUL
Q4 25
$-3.8M
$-64.7M
Q3 25
$-1.5M
$-69.4M
Q2 25
$-11.9M
$-67.8M
Q1 25
$-64.1M
Q4 24
$-48.4M
Q3 24
$-10.4M
$-36.5M
Q2 24
$-5.4M
$-43.8M
Q1 24
$-64.8M
Gross Margin
CAN
CAN
OCUL
OCUL
Q4 25
99.9%
88.0%
Q3 25
99.9%
87.8%
Q2 25
99.9%
85.6%
Q1 25
88.2%
Q4 24
92.8%
Q3 24
99.9%
89.9%
Q2 24
99.8%
90.8%
Q1 24
91.0%
Operating Margin
CAN
CAN
OCUL
OCUL
Q4 25
-15.9%
-526.5%
Q3 25
-27.0%
-472.3%
Q2 25
-45.5%
-502.6%
Q1 25
-597.5%
Q4 24
-296.1%
Q3 24
-77.2%
-298.2%
Q2 24
-193.9%
-265.1%
Q1 24
-214.0%
Net Margin
CAN
CAN
OCUL
OCUL
Q4 25
-18.4%
-488.0%
Q3 25
-11.0%
-477.3%
Q2 25
-104.4%
-503.9%
Q1 25
-598.7%
Q4 24
-283.3%
Q3 24
-102.7%
-236.6%
Q2 24
-112.3%
-266.3%
Q1 24
-438.9%
EPS (diluted)
CAN
CAN
OCUL
OCUL
Q4 25
$-0.05
$-0.27
Q3 25
$-0.02
$-0.38
Q2 25
$-0.25
$-0.39
Q1 25
$-0.38
Q4 24
$-0.25
Q3 24
$-0.22
Q2 24
$-0.26
Q1 24
$-0.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CAN
CAN
OCUL
OCUL
Cash + ST InvestmentsLiquidity on hand
$737.1M
Total DebtLower is stronger
$6.2M
Stockholders' EquityBook value
$52.4M
$654.3M
Total Assets
$92.5M
$808.1M
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CAN
CAN
OCUL
OCUL
Q4 25
$737.1M
Q3 25
$344.8M
Q2 25
$391.1M
Q1 25
$349.7M
Q4 24
$392.1M
Q3 24
$427.2M
Q2 24
$459.7M
Q1 24
$482.9M
Total Debt
CAN
CAN
OCUL
OCUL
Q4 25
$6.2M
Q3 25
$6.2M
Q2 25
$6.2M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CAN
CAN
OCUL
OCUL
Q4 25
$52.4M
$654.3M
Q3 25
$44.7M
$258.2M
Q2 25
$33.8M
$305.9M
Q1 25
$265.9M
Q4 24
$315.3M
Q3 24
$43.6M
$352.0M
Q2 24
$56.8M
$377.7M
Q1 24
$408.0M
Total Assets
CAN
CAN
OCUL
OCUL
Q4 25
$92.5M
$808.1M
Q3 25
$81.7M
$410.9M
Q2 25
$78.0M
$451.3M
Q1 25
$405.9M
Q4 24
$457.9M
Q3 24
$69.3M
$490.4M
Q2 24
$73.7M
$517.1M
Q1 24
$538.9M
Debt / Equity
CAN
CAN
OCUL
OCUL
Q4 25
0.12×
Q3 25
0.14×
Q2 25
0.18×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CAN
CAN
OCUL
OCUL
Operating Cash FlowLast quarter
$-54.2M
Free Cash FlowOCF − Capex
$-57.1M
FCF MarginFCF / Revenue
-430.9%
Capex IntensityCapex / Revenue
21.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-216.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CAN
CAN
OCUL
OCUL
Q4 25
$-54.2M
Q3 25
$-50.7M
Q2 25
$-55.2M
Q1 25
$-44.7M
Q4 24
$-39.4M
Q3 24
$-36.6M
Q2 24
$-24.8M
Q1 24
$-33.9M
Free Cash Flow
CAN
CAN
OCUL
OCUL
Q4 25
$-57.1M
Q3 25
$-56.7M
Q2 25
$-56.5M
Q1 25
$-46.6M
Q4 24
$-39.6M
Q3 24
$-36.6M
Q2 24
$-25.5M
Q1 24
$-34.1M
FCF Margin
CAN
CAN
OCUL
OCUL
Q4 25
-430.9%
Q3 25
-390.0%
Q2 25
-419.7%
Q1 25
-435.6%
Q4 24
-232.0%
Q3 24
-237.6%
Q2 24
-155.4%
Q1 24
-231.1%
Capex Intensity
CAN
CAN
OCUL
OCUL
Q4 25
21.4%
Q3 25
41.2%
Q2 25
9.3%
Q1 25
18.1%
Q4 24
1.2%
Q3 24
0.6%
Q2 24
4.5%
Q1 24
1.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons